Johnson & Johnson coronavirus vaccine gets better boost from Moderna or Pfizer, US study shows

Name: China considers mixing Covid-19 vaccine types to boost effectiveness
Uploaded: 2021-10-13T23:07:04.000Z
Duration: 2 min 1 s
Description: China considers mixing Covid-19 vaccine types to boost effectiveness

The findings by the National Institutes of Health come as an advisory group to the FDA prepares to discuss booster jabs for Moderna and J&J vaccines

The preliminary study also showed that ‘mixing and matching’ booster shots of different types is safe in adults

Reading Time:2 minutes

Why you can trust SCMP

FDA officials said J&J’s regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated. Photo: AP

Reuters

Published: 7:07am, 14 Oct 2021Updated: 10:24pm, 14 Oct 2021

People who got Johnson & Johnson Inc’s Covid-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc/BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday.

The study, which is preliminary and has not been peer reviewed, is the latest challenge to J&J’s efforts to use its Covid-19 vaccine as a booster in the United States.

The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that “mixing and matching” booster shots of different types is safe in adults. Moderna’s and Pfizer’s vaccines are based on messenger RNA while J&J’s uses viral vector technology.

It comes as an advisory group to the US Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&J vaccines.

02:01

China considers mixing Covid-19 vaccine types to boost effectiveness

FDA officials on Wednesday said J&J’s regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.